𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Preliminary clinical experience with the Bard XT coronary stent

✍ Scribed by Dimitrios Pentousis; Yves Guérin; Xavier Favereau; Hong Zheng; François Funck; Marcel Toussaint; Thierry Corcos

Book ID
117010869
Publisher
Elsevier Science
Year
1998
Tongue
English
Weight
233 KB
Volume
136
Category
Article
ISSN
1097-6744

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early experience with the Bard XT stent
Early experience with the Bard XT stent
✍ Ravat, Hasmukh ;Cannon, Adam 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB

The Bard XT stent is a new generation balloon expandable intracoronary stent. It has several unique design advantages. Between October 1996 and November 1997, 127 Bard XT stents of various length were deployed in 93 patients with 109 lesions. According to the American College of Cardiology (ACC) and

Initial clinical experience with the new
Initial clinical experience with the new EBI (BARD-XT) flexible coronary stent: Acute results and follow-up
✍ Sievert, Horst ;Rohde, Stephan ;Ensslen, Roland ;Fach, Andreas ;Merle, Hartmut ; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

The EBI (BARD-XT, C.R. Bard, Murray Hill, NJ) stent is a new radiopaque balloon expandable coronary stent with high resistance to external radial forces. It does not shorten significantly with expansion and allows stent implantation in bifurcation lesions. A total of 28 EBI stents were implanted in

Preliminary experience with the NIR coro
Preliminary experience with the NIR coronary stent
✍ Zheng, Hong ;Corcos, Thierry ;Favereau, Xavier ;Pentousis, Dimitrios ;Guérin, Yv 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB

We prospectively studied 223 patients (288 lesions) who underwent elective or bail out implantation of 309 NIR stents (Scimed, Boston Scientific Corporation, Galway, Ireland). Most lesions (68.4%) had unfavorable characteristics (type B2 or C). Primary success in stent deployment was achieved in 305